相似文献
1
Troponin elevation on admission and mortality after hospital discharge among patients with COVID-19.
Rev Assoc Med Bras (1992). 2023 May 19;69(5):e20230116. doi: 10.1590/1806-9282.20230116. eCollection 2023.
2
The Impact of COVID-19 Patients With Troponin Elevation on Renal Impairment and Clinical Outcome.
Cardiovasc Revasc Med. 2021 Dec;33:45-48. doi: 10.1016/j.carrev.2021.05.004. Epub 2021 May 8.
3
Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19.
Cardiovasc Revasc Med. 2021 Dec;33:41-44. doi: 10.1016/j.carrev.2021.03.002. Epub 2021 Mar 5.
4
Survival after hospital discharge in patients hospitalized for acute coronavirus disease 2019: data on 2586 patients from a tertiary center registry.
Croat Med J. 2022 Aug 31;63(4):335-342. doi: 10.3325/cmj.2022.63.335.
5
Patient and Hospital Factors Associated With Differences in Mortality Rates Among Black and White US Medicare Beneficiaries Hospitalized With COVID-19 Infection.
JAMA Netw Open. 2021 Jun 1;4(6):e2112842. doi: 10.1001/jamanetworkopen.2021.12842.
6
Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19).
Clin Infect Dis. 2023 Feb 8;76(3):e82-e89. doi: 10.1093/cid/ciac639.
7
Red cell distribution width is a potent prognostic parameter for in-hospital and post-discharge mortality in hospitalized coronavirus disease 2019 patients: a registry-based cohort study on 3941 patients.
Croat Med J. 2022 Feb 28;63(1):44-52. doi: 10.3325/cmj.2022.63.44.
8
Readmission rates of patients with COVID-19 after hospital discharge.
Rev Assoc Med Bras (1992). 2021 Nov;67(11):1610-1615. doi: 10.1590/1806-9282.20210675.
9
Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute Care Setting With Supplemental Oxygen.
JAMA Netw Open. 2021 Apr 1;4(4):e213990. doi: 10.1001/jamanetworkopen.2021.3990.
10
The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario.
CMAJ. 2022 May 16;194(19):E666-E673. doi: 10.1503/cmaj.220272.
本文引用的文献
1
Persistent cardiac injury - An important component of long COVID-19 syndrome.
EBioMedicine. 2022 Mar;77:103892. doi: 10.1016/j.ebiom.2022.103892. Epub 2022 Feb 23.
2
Biomarker evaluation for prognostic stratification of patients with COVID-19: the added value of quantitative chest CT.
Biomark Med. 2022 Mar;16(4):291-301. doi: 10.2217/bmm-2021-0536. Epub 2022 Feb 18.
3
Long-term cardiovascular outcomes of COVID-19.
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
4
More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
Sci Rep. 2021 Aug 9;11(1):16144. doi: 10.1038/s41598-021-95565-8.
5
Prognostic value of cardiac biomarkers in COVID-19 infection.
Sci Rep. 2021 Mar 2;11(1):4930. doi: 10.1038/s41598-021-84643-6.
6
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
7
Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System.
JAMA. 2021 Jan 19;325(3):304-306. doi: 10.1001/jama.2020.21465.
8
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.
Nat Rev Cardiol. 2021 Mar;18(3):194-209. doi: 10.1038/s41569-020-00469-1. Epub 2020 Nov 19.
9
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557.
10
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
Zotero 插件